Browse > Article
http://dx.doi.org/10.3857/roj.2014.32.1.7

Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer  

Im, Jung Ho (Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine)
Seong, Jinsil (Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine)
Lee, Jeongshim (Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine)
Kim, Yong Bae (Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine)
Lee, Ik Jae (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine)
Park, Jun Sung (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine)
Yoon, Dong Sup (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine)
Kim, Kyung Sik (Department of Surgery, Severance Hospital, Yonsei University College of Medicine)
Lee, Woo Jung (Department of Surgery, Severance Hospital, Yonsei University College of Medicine)
Publication Information
Radiation Oncology Journal / v.32, no.1, 2014 , pp. 7-13 More about this Journal
Abstract
Purpose: To evaluate the results of postoperative radiotherapy in patients with extra-hepatic bile duct cancer (EHBDC) and identify the prognostic factors for local control and survival. Materials and Methods: Between January 2001 and December 2010, we retrospectively reviewed the cases of 70 patients with EHBDC who had undergone curative resection and received postoperative radiotherapy. The median radiation dose was 50.4 Gy (range, 41.4 to 54 Gy). The resection margin status was R0 in 30 patients (42.9%), R1 in 25 patients (35.7%), and R2 in 15 patients (21.4%). Results: The 5-year rates of overall survival (OS), event-free survival (EFS), and locoregional control (LRC) for all patients were 42.9%, 38.3%, and 61.2%, respectively. The major pattern of failure was distant relapses (33 patients, 47.1%). A multivariate analysis showed that the postradiotherapy CA19-9 level, radiation dose (${\geq}50$ Gy), R2 resection margins, perineural invasion, and T stage were the significant prognostic factors for OS, EFS, and LRC. OS was not significantly different between the patients receiving R0 and R1 resections, but was significantly lower among those receiving R2 resection (54.6%, 56.1%, and 7.1% for R0, R1, and R2 resections, respectively). Conclusion: In patients with EHBDC who had undergone curative resection, a postoperative radiotherapy dose less than 50 Gy was suboptimal for OS and LRC. Higher radiation doses may be needed to obtain better LRC. Further investigation of novel therapy or palliative treatment should be considered for patients receiving R2 resection.
Keywords
Bile duct neoplasms; Adjuvant radiotherapy; Radiotherapy dosage;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol J 2012;30:197-204.   DOI
2 Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853-9.   DOI
3 Matsuda T, Fujita H, Harada N, et al. Impact of adjuvant radiation therapy for microscopic residual tumor after resection of extrahepatic bile duct cancer. Am J Clin Oncol 2013;36:461-5.   DOI
4 Choi SB, Park SW, Kim KS, Choi JS, Lee WJ. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol 2009;99: 335-42.   DOI   ScienceOn
5 Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696-704.   DOI
6 Kim K, Chie EK, Jang JY, et al. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol 2012;35: 136-40.   DOI
7 Oh D, Lim DH, Heo JS, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol 2007;30:21-5.   DOI   ScienceOn
8 Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46: 581-7.   DOI   ScienceOn
9 Todoroki T, Kawamoto T, Koike N, Fukao K, Shoda J, Takahashi H. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg 2001;88:364-70.   DOI   ScienceOn
10 Gerhards MF, van Gulik TM, Gonzalez DG, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003;27:173-9.
11 Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178-82.   DOI   ScienceOn
12 Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol 2007;33:202-7.   DOI
13 Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-8.   DOI   ScienceOn
14 Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45:1-14.   DOI   ScienceOn
15 Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.   DOI   ScienceOn
16 Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73.   DOI   ScienceOn
17 Kim JK, Ha HK, Han DJ, Auh YH. CT analysis of postoperative tumor recurrence patterns in periampullary cancer. Abdom Imaging 2003;28:384-91.   DOI
18 Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700.   DOI   ScienceOn
19 Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-97.   DOI   ScienceOn
20 Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 2005;35:548-52.   DOI   ScienceOn
21 Reding R, Buard JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded): results of the French Surgical Association Survey. Ann Surg 1991;213:236-41.   DOI   ScienceOn
22 Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008;15:3147-56.   DOI   ScienceOn